Dividend Overview
Dividend Yield
—
Dividend / Share
—
Nexalin Technology Inc
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
Holds 654783.0x more cash than debt — a strong balance sheet.
Current Price
$0.38
+0.03%GoodMoat Value
$0.08
79.4% overvaluedDividend Yield
—
Dividend / Share
—
Market Cap
$7.10M
P/E Ratio
-0.86
Forward P/E
—
EPS
$-0.50
PEG Ratio
0.02
Book Value
$0.20
Dividend Yield
—
Profit Margin
-2725.76%
ROE
-219.38%
Nexalin Technology Inc (NXL) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: -0.86. Profit margin: -2725.76%. Free cash flow: $-4.96M. This page shows Nexalin Technology Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Nexalin Technology Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.